The Apollo Hospital, Chennai had recently successfully completed four back-to-back MitraClip procedures in a single day, achieving a milestone that is first in the Asian continent, according to a press release. The MitraClip implants were carried out on four patients suffering from severe heart failure on the same day by Dr Sai Satish, Senior Interventional Cardiologist, Apollo Hospitals.
MitraClip provides a non-surgical alternative to treat patients with mitral valve leaks (mitral regurgitation), which can lead to cardiac failure. The non-surgical method avoids open-heart surgery and instead approaches the heart through a catheter inserted through a vein in the thigh. The device is delivered to the heart using the catheter under real time 3D echocardiographic & fluoroscopic guidance.
Apollo Hospitals is also developing the Echo Connect Project that will allow scaling up of this programme to detect leaking mitral valves at a nationwide level. Dr Sai Satish working with Prof. K Chandrashekaran, Sr. Consultant Cardiologist at Apollo Hospitals, Chennai envisages the Echo Connect Project to enable specialists in Chennai to provide an expert opinion on echocardiography conducted across the country, detect a defective mitral valve and refer them to Apollo Chennai for MitraClip procedure.
“We have been performing MitraClip procedures for about three years now. It was the confidence gained through our extensive experience that enabled us to perform back-to-back MitraClip implants in four very sick patients in just one day. In fact, while the original plan was to only operate on 2 patients that day, the other 2 decompensated rapidly and needed immediate attention as well. With the support of an experienced team working seamlessly in tandem, we were able to successfully complete the four back-to-back MitraClip procedures like clockwork.” said Dr. Sai Satish.
The MitraClip is the only percutaneous technology effective in both functional and degenerative mitral regurgitation. The device is removable and repositionable.
“For a properly selected patient who is at high surgical risk, MitraClip is actually economical in the long run as repeat hospitalisations are avoided. More important, however, is the fact that the patient gets a new lease of life by regaining his or her quality of life and by being able to pursue an active normal lifestyle once again.” added Dr Satish.
MitraClip is becoming the standard of care for patients with heart failure with moderate to severe or severe primary and secondary mitral regurgitation who are not improving on medical treatment.
According to a recent landmark trial (COAPT trial), transcatheter mitral valve repair using the MitraClip along with guideline-directed medical therapy (GDMT) was superior to GDMT alone in reducing hospitalisation for heart failure (HF) and mortality in symptomatic HF patients with grade 3-4+ mitral regurgitation. Improvements were also observed in left ventricule (LV) dimensions and patient symptoms. Along with safety, significant improvements were noted in quality of life measurements starting at 1 month and sustained out to 24 months, showed the research.